MDM2 and cancer: The seminal work of Julio Camarero and colleagues revealing that MCoTI-II cyclotide carrying hDM2/Mdm2 peptides can activate the p53 tumor suppressor pathway and block tumor growth in a human colorectal carcinoma xenograft mouse model [76] opened up a new chapter of research in the field as it relates to the anti-cancer activity of grafted cyclotides [27,29].